AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic shocks
Number of subjects: 5
Study 8160603 — intervention group
Group type: COMPARATOR
Intervention: Sequential monophasic shocks
Number of subjects: 5
Study 8160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic shocks with bidirectional lead configuration
Number of subjects: 5
Study 8160603 — intervention group
Group type: COMPARATOR
Intervention: Biphasic shocks with bidirectional lead configuration
Number of subjects: 5
Study 8160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic shocks with unidirectional lead configuration
Number of subjects: 5
Study 8160603 — intervention group
Group type: COMPARATOR
Intervention: Biphasic shocks with unidirectional lead configuration
Number of subjects: 5
Study 8160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar transvenous defibrillation lead system ('active can')
Number of subjects: 5
Study 8160603 — intervention group
Group type: COMPARATOR
Intervention: Standardized unidirectional lead configuration
Number of subjects: 5
Study 3046587 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45
Study 3046587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections (MI)
Number of subjects: 45
Study 3046587 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 45
Study 29016150 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterstereotypic imagined intergroup contact
Number of subjects: 0
Study 29016150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotypic imagined intergroup contact
Number of subjects: 0
Study 29016150 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26823484 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents
Number of subjects: 6081
Study 26823484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 6081
Study 26823484 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 6081
Study 26182820 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian turmeric powder with honey
Number of subjects: 60
Study 26182820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 22592178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bikram yoga training (24 sessions in 8 weeks)
Number of subjects: 21
Study 22592178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 21739240 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-policosanol (MP) 20 mg daily with background statin therapy
Number of subjects: 54
Study 21739240 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-policosanol (MP) 20 mg daily as monotherapy
Number of subjects: 54
Study 21739240 — intervention group
Group type: COMPARATOR
Intervention: Placebo with background statin therapy
Number of subjects: 54
Study 19564517 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who have been tested for HIV
Number of subjects: 2107
Study 19564517 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics affecting HIV testing history
Number of subjects: 2107
Study 19564517 — intervention group
Group type: EXPERIMENTAL
Intervention: Age relationship to HIV testing history
Number of subjects: 2107
Study 19564517 — intervention group
Group type: EXPERIMENTAL
Intervention: Education years relation to HIV testing history
Number of subjects: 2107
Study 17024505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g daily)
Number of subjects: 303
Study 17024505 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (2 g every 12 h with optional metronidazole 500 mg every 12 h)
Number of subjects: 303
Study 17024505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 303
Study 17024505 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 303
Study 15219514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous bone marrow mesenchymal stem cell
Number of subjects: 69
Study 15219514 — intervention group
Group type: COMPARATOR
Intervention: Standard saline
Number of subjects: 69
Study 11174623 — intervention group
Group type: EXPERIMENTAL
Intervention: First-phase insulin release during IV-GTT
Number of subjects: 59600
Study 11174623 — intervention group
Group type: EXPERIMENTAL
Intervention: Children <8 years
Number of subjects: 59600
Study 11174623 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects 8 to 20 years
Number of subjects: 59600
Study 9287229 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 220
Study 9287229 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 220
Study 8501503 — intervention group
Group type: EXPERIMENTAL
Intervention: VCMP/VBAP combination chemotherapy
Number of subjects: 487
Study 8501503 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan-prednisone)
Number of subjects: 487
Study 3226837 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to sugar
Number of subjects: 90
Study 3226837 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (additional controls added)
Number of subjects: 90
Study 30005643 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention with monthly group education on diabetic retinopathy (DR) and individual reminders for eye examination
Number of subjects: 700
Study 30005643 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices alone
Number of subjects: 700
Study 28511614 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP-CE (new topical panthenol-containing emollient)
Number of subjects: 108
Study 28511614 — intervention group
Group type: COMPARATOR
Intervention: Reference emollient
Number of subjects: 108
Study 25626962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation of both the clavicle and the scapular neck (group A)
Number of subjects: 39
Study 25626962 — intervention group
Group type: COMPARATOR
Intervention: Fixation of the clavicle alone (group B)
Number of subjects: 39
Study 25626962 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (group C)
Number of subjects: 39
Study 23107362 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling in Dialogue (CD)
Number of subjects: 94
Study 23107362 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CU)
Number of subjects: 94
Study 17148515 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation in the home setting (9 hours/week for three weeks)
Number of subjects: 58
Study 17148515 — intervention group
Group type: COMPARATOR
Intervention: Day clinic rehabilitation
Number of subjects: 58
Study 12535822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/daily
Number of subjects: 110
Study 12535822 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/daily
Number of subjects: 110
Study 12535822 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 110
Study 10825055 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (400 mg/d for 1 week, then 200 mg/d for 7 weeks)
Number of subjects: 16
Study 10825055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10825055 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 16
Study 7595132 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaliuretic peptide (100 ng/kg body weight/min for 60 min)
Number of subjects: 30
Study 7595132 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting natriuretic peptide (100 ng/kg body weight/min for 60 min)
Number of subjects: 30
Study 7595132 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) (100 ng/kg body weight/min for 60 min)
Number of subjects: 30
Study 7595132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel dilator (100 ng/kg body weight/min for 60 min)
Number of subjects: 30
Study 7595132 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaliuretic peptide, ANF, and long acting natriuretic peptide (100 ng/kg body weight/min for 60 min)
Number of subjects: 30
Study 2125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily for 1 week
Number of subjects: 20
Study 2125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once daily for 1 week
Number of subjects: 20
Study 2125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 20
Study 2125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 20
Study 2125605 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin and Lovastatin
Number of subjects: 20
Study 7382968 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. ribostamycin
Number of subjects: 30
Study 7382968 — intervention group
Group type: COMPARATOR
Intervention: i.m. gentamycin
Number of subjects: 30
Study 29460236 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN-D0103 50 mg bd
Number of subjects: 21
Study 29460236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27124878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% BID
Number of subjects: 0
Study 27124878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% QD
Number of subjects: 0
Study 27124878 — intervention group
Group type: COMPARATOR
Intervention: Vehicle BID
Number of subjects: 0
Study 25591488 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrofusion
Number of subjects: 221
Study 25591488 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (diathermy or cold scalpel)
Number of subjects: 221
Study 22968837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39
Study 22968837 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 39
Study 20583937 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.125% with fentanyl 100 microg
Number of subjects: 80
Study 20583937 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 0.2% with fentanyl 100 microg
Number of subjects: 80
Study 17976714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant-related targets in the absence of a biasing context
Number of subjects: 0
Study 17976714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dominant- and subordinate-related targets in the absence of a biasing context
Number of subjects: 0
Study 17976714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant-related targets in the presence of a biasing context
Number of subjects: 0
Study 17976714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dominant- and subordinate-related targets in the presence of a biasing context
Number of subjects: 0
Study 15990709 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybin + vitamin E + phospholipids
Number of subjects: 85
Study 12695268 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 21
Study 10495843 — intervention group
Group type: EXPERIMENTAL
Intervention: VigiMouse visual performance test
Number of subjects: 6
Study 10495843 — intervention group
Group type: COMPARATOR
Intervention: Visual analogue scale
Number of subjects: 6
Study 7560236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride
Number of subjects: 57
Study 7560236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 57
Study 7560236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 1951080 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐8212 (60 mg/day)
Number of subjects: 76
Study 1951080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 6974386 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 827
Study 6974386 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine against Hemophilus influenzae type b
Number of subjects: 827
Study 31498390 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SEARCH + ASD Supports (PS + ASD) intervention
Number of subjects: 14
Study 31498390 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (special education transition services)
Number of subjects: 14
Study 29860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight reappraisal
Number of subjects: 0
Study 29860928 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple reappraisal
Number of subjects: 0
Study 29860928 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27841849 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical apraclonidine 0.5%
Number of subjects: 39
Study 27841849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26072348 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann isopters III4e, I4e, and I2e
Number of subjects: 154
Study 26072348 — intervention group
Group type: EXPERIMENTAL
Intervention: Octopus isopters III4e and I4e
Number of subjects: 154
Study 26072348 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey mean deviation (MD)
Number of subjects: 154
Study 23129812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 82
Study 23129812 — intervention group
Group type: COMPARATOR
Intervention: Full manipulative group (mid-cervical, cervico-thoracic and thoracic joint manipulations)
Number of subjects: 82
Study 20346703 — intervention group
Group type: EXPERIMENTAL
Intervention: PepCO(2)
Number of subjects: 60
Study 20346703 — intervention group
Group type: COMPARATOR
Intervention: PaCO(2)tc
Number of subjects: 60
Study 20346703 — intervention group
Group type: COMPARATOR
Intervention: PaCO(2)tu
Number of subjects: 60
Study 19809393 — intervention group
Group type: EXPERIMENTAL
Intervention: Friedreich Ataxia Rating Scale (FARS)
Number of subjects: 38
Study 19809393 — intervention group
Group type: COMPARATOR
Intervention: Gait parameters (velocity, cadence, stride length)
Number of subjects: 38
Study 17760597 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injections at the vermilion border, 1 week before chemabrasion
Number of subjects: 12
Study 17760597 — intervention group
Group type: COMPARATOR
Intervention: Control sides (no BoNTA injections)
Number of subjects: 12
Study 15467100 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) rehydrated with Coca‐Cola
Number of subjects: 10
Study 15467100 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free (CF) rehydrated with Caffeine‐Free Coca‐Cola
Number of subjects: 10
Study 11169020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose L-5-methyltetrahydrofolate (MTHF) at 17 mg/day
Number of subjects: 50
Study 11169020 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA) at 15 mg/day
Number of subjects: 50
Study 11169020 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) at 2.4 mg/day (for RTRs)
Number of subjects: 50
Study 11169020 — intervention group
Group type: COMPARATOR
Intervention: High-dose oral MTHF (17 mg/day) or FA (15 mg/day) (for HD patients)
Number of subjects: 50
Study 9701162 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn with micronutrients (ZM)
Number of subjects: 740
Study 9701162 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn alone (Z)
Number of subjects: 740
Study 9701162 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients alone (M)
Number of subjects: 740
Study 7748921 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline examination including interviews, physical exams, and laboratory tests.
Number of subjects: 5632
Study 7748921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing interim hospital discharge data survey and mortality survey.
Number of subjects: 5632
Study 2812836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural administration of fentanyl (1 microgram/kg body weight)
Number of subjects: 6
Study 2812836 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of fentanyl (1 microgram/kg body weight)
Number of subjects: 6
Study 2812836 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 6
Study 970905 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis (20-60 mg) in the short-perfusion group (9 patients)
Number of subjects: 45
Study 970905 — intervention group
Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the short-perfusion group (15 patients)
Number of subjects: 45
Study 970905 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis (20-60 mg) in the long-perfusion group (13 patients)
Number of subjects: 45
Study 970905 — intervention group
Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the long-perfusion group (11 patients)
Number of subjects: 45
Study 970905 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis in the short-perfusion group
Number of subjects: 45
Study 970905 — intervention group
Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the short-perfusion group
Number of subjects: 45
Study 970905 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis in the long-perfusion group
Number of subjects: 45
Study 970905 — intervention group
Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the long-perfusion group
Number of subjects: 45
Study 31841354 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus paclitaxel
Number of subjects: 140
Study 31841354 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 140
Study 31841354 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered tumors
Number of subjects: 140
Study 31841354 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered tumors
Number of subjects: 140
Study 30971437 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-propionate ester (IPE)
Number of subjects: 12
Study 30971437 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 12
Study 30971437 — intervention group
Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 12
Study 27981854 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable blades at 1500 rpm
Number of subjects: 48
Study 27981854 — intervention group
Group type: COMPARATOR
Intervention: Reusable blades at 1500 rpm
Number of subjects: 48
Study 27981854 — intervention group
Group type: EXPERIMENTAL
Intervention: Total morcellation rate using disposable blades
Number of subjects: 48
Study 27981854 — intervention group
Group type: COMPARATOR
Intervention: Single-use blades at 850 rpm
Number of subjects: 48
Study 27981854 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use blades at 1500 rpm
Number of subjects: 48
Study 26409520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition-based context prompting
Number of subjects: 42
Study 26409520 — intervention group
Group type: COMPARATOR
Intervention: Time-based prompting (every 5 minutes)
Number of subjects: 42
Study 23985437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.5% arginine and 1450 ppm fluoride
Number of subjects: 284
Study 23985437 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice containing 1450 ppm fluoride
Number of subjects: 284
Study 23985437 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 284
Study 22208783 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 10 mg daily
Number of subjects: 30
Study 22208783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18582572 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin under fasting conditions
Number of subjects: 0
Study 18582572 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin after intake at the beginning of breakfast
Number of subjects: 0
Study 18582572 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin after breakfast
Number of subjects: 0
Study 18582572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavulanic acid under fasting conditions
Number of subjects: 0
Study 18582572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavulanic acid after intake at the beginning of breakfast
Number of subjects: 0
Study 18582572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavulanic acid after breakfast
Number of subjects: 0
Study 16607936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerasorb (beta-tricalcium phosphate)
Number of subjects: 17
Study 16607936 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 17
Study 12828845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PIR, b.i.d. for one week, then titrated to 1% PIR for one week, then 2% PIR for two weeks, and then for an additional 11 months
Number of subjects: 26
Study 12828845 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 26
Study 12828845 — intervention group
Group type: EXPERIMENTAL
Intervention: PIR (various concentrations)
Number of subjects: 26
Study 10935581 — intervention group
Group type: EXPERIMENTAL
Intervention: DPNB ligated (group 1)
Number of subjects: 28
Study 10935581 — intervention group
Group type: EXPERIMENTAL
Intervention: DPNB preserved (group 2)
Number of subjects: 28
Study 10935581 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3, unoperated)
Number of subjects: 28
Study 8813918 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% mannitol (group A)
Number of subjects: 59
Study 8813918 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glycine (group B)
Number of subjects: 59
Study 8813918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7% sorbitol and 0.54% mannitol (group C)
Number of subjects: 59
Study 1363664 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy (psychotherapy, relaxation, etc.) alone in group I (9 patients)
Number of subjects: 18
Study 1363664 — intervention group
Group type: COMPARATOR
Intervention: Psychosomatic therapy plus treatment with amineptine and clobazam in group II (9 patients)
Number of subjects: 18
Study 3910303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg + Acebutolol 100 mg
Number of subjects: 114
Study 3910303 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol 200 mg
Number of subjects: 114